Aristeia Capital’s BridgeBio Pharma BBIO Stock Holding History

Aristeia Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23,582	Closed	-$815K	–	493
2025 Q1	$815K	Sell	23,582 -388,345	-94%	-$13.1M	0.02%	144
2024 Q4	$11.3M	Buy	411,927 +275,340	+202%	+$7.12M	0.37%	38
2024 Q3	$3.48M	Buy	136,587 +60,365	+79%	+$1.58M	0.07%	95
2024 Q2	$1.93M	Buy	+76,222	New	+$2.08M	0.04%	89
2023 Q1	–	Sell	-195,711	Closed	-$1.49M	–	387
2022 Q4	$1.49M	Buy	195,711 +45,711	+30%	+$438K	0.03%	306
2022 Q3	$1.49M	Sell	150,000 -400,000	-73%	-$4.16M	0.03%	387
2022 Q2	$4.99M	Buy	550,000 +502,100	+1,048%	+$4.2M	0.09%	268
2022 Q1	$486K	Buy	+47,900	New	+$492K	0.01%	398

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Aristeia Capital's BBIO Position: Q2 2025 in Review

Aristeia Capital sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 23,582 shares — an estimated $815K sold.

Aristeia Capital first reported a position in BBIO in Q1 2022 and held it in 8 quarters. The position peaked at $11.3M in Q4 2024. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Aristeia Capital reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Aristeia Capital sold 23,582 BridgeBio Pharma shares in Q2 2025, an estimated $815K.
Aristeia Capital first reported a position in BridgeBio Pharma in Q1 2022 and held it in 8 quarters.
Aristeia Capital's BridgeBio Pharma position peaked at $11.3M in Q4 2024.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Aristeia Capital's 13F filing for Q2 2025, filed 14 Aug 2025.